Barclays raised the firm’s price target on Iovance Biotherapeutics to $22 from $18 and keeps an Overweight rating on the shares. The analyst updated the model post the company’s Q4 and is encouraged by initial demand for Amtagvi.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
- IOVA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insiders Pour Millions Into These 2 Buy-Rated Stocks; Here’s Why You Might Want to Follow Their Lead
- Biotech Alert: Searches spiking for these stocks today
- Iovance Biotherapeutics call volume above normal and directionally bullish
